DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Arms (1)

1. type

   EXPERIMENTAL

   label

   Diagnostic (DCE-MRI, MBI)

   description

   Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).

   interventionNames

   1. Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
   2. Other: Laboratory Biomarker Analysis
   3. Radiation: Scintimammography
   4. Drug: Technetium Tc-99m Sestamibi

Primary outcomes (3)

1. measure

   Percent change in volume of index tumors and estimated area under receiver operating characteristic (ROC) curves assessed by digital mammogram, ultrasound, dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and molecular breast imaging (MBI)

   timeFrame

   Up to 4 years

   description

   The ability to assess and predict response will be compared among the imaging modalities and with standard pathological evaluation. These volume changes will be correlated with residual cancer burden (RCB) status after surgery and will be used to classify patients into predicted responder or non-responder categories. Predictive accuracies among the imaging modalities will be compared using paired ROC curve analyses.